NDAINHALATIONGAS
Approved
Dec 2015
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
2/8 — Basic
MEDICAL AIR, USP (medical air) by Connect Biopharma. Approved for idiopathic pulmonary fibrosis. First approved in 2015.
Drug data last refreshed 21h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MEDICAL AIR, USP is an inhalation gas product approved for Idiopathic Pulmonary Fibrosis (IPF), a progressive lung disease. The product represents a non-pharmacological therapeutic intervention in a disease area dominated by small-molecule inhibitors. Medical air delivery addresses respiratory support in IPF patients.
Peak
Product is at peak lifecycle stage with moderate competitive pressure (30%), but current commercial spending data is unavailable; team size and growth trajectory remain uncertain.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Worked on MEDICAL AIR, USP at Connect Biopharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.